Cite
Persistence of apremilast in moderate‐to‐severe psoriasis: a real‐world analysis of 14 147 apremilast‐ and methotrexate‐naive patients in the French National Health Insurance database.
MLA
Sbidian, E., et al. “Persistence of Apremilast in Moderate‐to‐severe Psoriasis: A Real‐world Analysis of 14 147 Apremilast‐ and Methotrexate‐naive Patients in the French National Health Insurance Database.” British Journal of Dermatology, vol. 182, no. 3, Mar. 2020, pp. 690–97. EBSCOhost, https://doi.org/10.1111/bjd.18047.
APA
Sbidian, E., Billionnet, C., Weill, A., Maura, G., & Mezzarobba, M. (2020). Persistence of apremilast in moderate‐to‐severe psoriasis: a real‐world analysis of 14 147 apremilast‐ and methotrexate‐naive patients in the French National Health Insurance database. British Journal of Dermatology, 182(3), 690–697. https://doi.org/10.1111/bjd.18047
Chicago
Sbidian, E., C. Billionnet, A. Weill, G. Maura, and M. Mezzarobba. 2020. “Persistence of Apremilast in Moderate‐to‐severe Psoriasis: A Real‐world Analysis of 14 147 Apremilast‐ and Methotrexate‐naive Patients in the French National Health Insurance Database.” British Journal of Dermatology 182 (3): 690–97. doi:10.1111/bjd.18047.